Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tafenoquine - GlaxoSmithKline/60 Degrees Pharmaceuticals

Next Previous
Drug Profile

Tafenoquine - GlaxoSmithKline/60 Degrees Pharmaceuticals

Alternative Names: 60P 003; Arakoda; Etaquine; KODATEF; Kozenis; Krintafel; SB-252263; SB-252263-AAB; SB-252263-AX; Tafenoquine maleate; Tafenoquine succinate; WR 238605; WR 238605 succinate

Latest Information Update: 04 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Walter Reed Army Institute of Research
  • Developer 60 Degrees Pharmaceuticals; Biocelect; GlaxoSmithKline; Medicines for Malaria Venture
  • Class Aminoquinolines; Antimalarials; Antiprotozoals; Small molecules
  • Mechanism of Action Electron transport complex III inhibitors; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malaria
  • Discontinued Babesiosis; Pneumocystis pneumonia

Most Recent Events

  • 03 Dec 2019 60 Degrees Pharmaceuticals receives a patent for treatment of Malaria with Arakoda™ (Tafenoquine) tablets in USA
  • 21 Nov 2019 Launched for Malaria (Prevention, In adults) in USA (PO)
  • 31 Oct 2019 Registered for Malaria (In adolescents, In adults) in Brazil (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top